



**NeuroScientific**  
BIOPHARMACEUTICALS

Level 1, 45 Stirling Highway  
Nedlands WA 6009 Australia  
[www.neuroscientific.com](http://www.neuroscientific.com)

## **NeuroScientific Invited to Present at BIO Investor Forum in San Francisco**

**Perth, Australia; 14 August 2019:** Drug development company NeuroScientific Biopharmaceuticals Ltd (ASX:NSB, “NSB” or the “Company”) is pleased to announce that the Company has been invited to present at the BIO Investor Forum to be held in San Francisco, CA on October 22-23, 2019.

The annual BIO Investor Forum is an international biotech investor conference focused on investment trends and opportunities in life sciences. The conference is expected to attract more than 1,000 attendees from private equity and public investors, research analysts and pharma industry executives focused on investment and business development opportunities in life sciences making it one of the largest conferences of its kind globally. To date, NeuroScientific Biopharmaceuticals is the only Australian company to be invited to present at the conference.

The search for an effective treatment of neurological diseases such as Alzheimer’s is considered the ‘holy grail’ in drug research and is evidenced by increased investment activity from blue chip US hedge funds and venture capital into the sector. NSB’s novel approach to cell survival was considered ‘radical’ at the time of its listing mid-last year but now is likely to be considered mainstream by the scientific community as interest in this space inevitably intensifies.

“Following on from highly successful meetings held at the BIO2019 conference in Philadelphia, we are delighted to be given the opportunity to create further awareness of NeuroScientific Biopharmaceuticals at the BIO Investor Forum by presenting our novel approach to neurological disease in front of such a large and diverse international audience”, said CEO and Managing Director Matt Liddelow.

### **About NeuroScientific Biopharmaceuticals Ltd**

NSB (ASX:NSB) is a drug development company focused on developing peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need. The Company’s product portfolio includes EmtinB, a novel therapeutic peptide most advanced as a treatment for Alzheimer’s disease; and other related peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit [www.neuroscientific.com](http://www.neuroscientific.com)

### **Contacts**

Mr Matthew Liddelow  
CEO and Managing Director  
[ml@neuroscientific.com](mailto:ml@neuroscientific.com)  
+61 8 6382 1805

Thomas Spencer  
CFO & Company Secretary  
[ir@neuroscientific.com](mailto:ir@neuroscientific.com)  
+61 491 108 250